Tuhura Biosciences, Inc/nv S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
TuHURA Biosciences, a clinical-stage immuno-oncology company, filed an S-1/A registration statement for the resale of up to 9.3 million shares, following recent mergers and financing activities.
NASDAQ
TuHURA Biosciences progresses its immuno-oncology pipeline with a Phase 3 trial initiation and strategic acquisition, while facing significant financial challenges and a need for substantial additional funding.